Evidence map›Paper›PMID 30377786›Full record

ReviewDer Pathologe2018

[Clonal evolution of early lymphoproliferations].

F Fend, L Quintanilla-Martinez

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Pathologe, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

F FendInstitut für Pathologie und Neuropathologie, Universitätsklinikum Tübingen, Eberhard-Karls-Universität Tübingen, Liebermeisterstraße 8, 72076, Tübingen, Deutschland. falko.fend@med.uni-tuebingen.de.
L Quintanilla-MartinezInstitut für Pathologie und Neuropathologie, Universitätsklinikum Tübingen, Eberhard-Karls-Universität Tübingen, Liebermeisterstraße 8, 72076, Tübingen, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The identification and molecular characterisation of premalignant precursor lesions of lymphomas, such as monoclonal gammopathy of unknown significance (MGUS) and the so-called in situ lymphoproliferations, has made significant progress in the recent years. The in situ follicular neoplasia (ISFN), the best-characterised entity, is by definition not identifiable by morphology and represents a t(14;18)+ precursor lesion of follicular lymphoma with characteristic immunophenotype, low potential for progression, and already identifiable secondary genetic alterations. The use of high-throughput genetic techniques on microdissected tissues has generated novel insights into clonal evolution and biological progression of early lesions and documented that an isolated genetic analysis is insufficient to understand the complexity of proliferations.

Indexed as

Lymphoma, FollicularMonoclonal Gammopathy of Undetermined SignificanceMultiple MyelomaPrecancerous ConditionsClonal EvolutionDisease ProgressionHumansCell proliferationClonal evolutionFollicular lymphomaGenetic testingIn situ follicular neoplasiaMonoclonal gammopathy of undetermined significance

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.